Saadat Pakeezah, Bansback Nick, Falahee Marie, Hiligsmann Mickaël, Tugwell Peter, Buchbinder Rachelle, Whittle Samuel, Richards Dawn P, Proulx Laurie, Schunemann Holger, Alonso-Coello Pablo, Nieuwlaat Robby, Wiercioch Wojtek, Kuper Simon, Pardo Pardo Jordi, Hazlewood Glen
Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.
School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada.
BMJ Open. 2025 Jan 15;15(1):e088267. doi: 10.1136/bmjopen-2024-088267.
The pharmacological management of inflammatory arthritis often requires choices that involve trade-offs between benefits, risks and other attributes such as administration route, frequency and cost. This living systematic review aims to inform international clinical guidelines on inflammatory arthritis by creating an evidence map of patient preference studies concerning the trade-offs in pharmacological management of inflammatory arthritis.
We will include published and peer-reviewed full-text studies in any language that quantitatively assess preferences of patients for the pharmacological management of inflammatory arthritis (rheumatoid arthritis, spondyloarthritis and juvenile idiopathic arthritis). Studies must use either stated or revealed preference methods to assess preferences and provide a quantitative assessment of relevant characteristics, such as benefits, risks, costs and process attributes. Articles will identified through Medline and EMBASE database searches from inception using search terms that combine keywords and subject headings for inflammatory arthritis and preference-based methods, and a search in the Health Preference Study and Technology Registry using keywords for the populations of interest. Two independent reviewers will perform abstract and full-text screening. Risk of bias will be assessed using the GRADE risk of bias tool. An evidence map will be generated to summarise included studies and their assessments of each trade-off. The search will be conducted every 6 months with new studies added to the inventory.
Ethics approval is not required. Results from the base review will be published in a peer-reviewed journal and findings will be presented at conferences. In the living model, we will publish updates and datasets on an Open Science Framework page, with periodic updates in peer-reviewed journals.
炎症性关节炎的药物治疗通常需要在获益、风险以及其他属性（如给药途径、频率和成本）之间进行权衡后做出选择。本循证系统综述旨在通过创建关于炎症性关节炎药物治疗权衡的患者偏好研究证据图谱，为国际炎症性关节炎临床指南提供参考。
我们将纳入以任何语言发表并经过同行评审的全文研究，这些研究需定量评估患者对炎症性关节炎（类风湿关节炎、脊柱关节炎和幼年特发性关节炎）药物治疗的偏好。研究必须使用陈述性或显示性偏好方法来评估偏好，并对相关特征（如获益、风险、成本和过程属性）进行定量评估。文章将通过从创刊号开始在Medline和EMBASE数据库中检索来识别，检索词结合了炎症性关节炎的关键词和主题词以及基于偏好的方法，并在健康偏好研究与技术注册库中使用感兴趣人群的关键词进行检索。两名独立评审员将进行摘要和全文筛选。将使用GRADE偏倚风险工具评估偏倚风险。将生成一个证据图谱，以总结纳入的研究及其对每个权衡的评估。每6个月进行一次检索，并将新研究添加到清单中。
无需伦理批准。基础综述的结果将发表在同行评审期刊上，研究结果将在会议上展示。在动态模型中，我们将在开放科学框架页面上发布更新内容和数据集，并在同行评审期刊上定期更新。
